After a stroke, the BBB damage could allow the serum antibodies to rapidly access their target in the CNS and limit the damage, as suggested by the smaller infarct volume in NMDAR-Abs seropositive non-APOE4 carriers (29). The gene discussed is APOE; the disease is Stroke.